Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Synektik Spólka Akcyjna (SNT.WA)
PLN394.00
+1.60 (+0.41%)
PL WSE Healthcare Medical - Devices
Address
ul. Józefa Piusa Dziekonskiego 3 00-728
Warsaw, PL
Warsaw, PL
CEO
Cezary Dariusz Kozanecki
Website
synektik.com.pl
IPO
2011-08-01
ISIN PLSNKTK00019
Description
Synektik Spólka Akcyjna, founded in 2001 and headquartered in Warsaw, Poland, operates as a comprehensive provider of products, services, and information technology solutions within the Polish market. The company focuses its offerings on the fields of surgery, diagnostic imaging, and nuclear medicine. Its core business activities include the distribution of medical equipment utilized in diagnostics, therapy, and nuclear medicine, alongside the creation of specialized IT solutions for radiology. Synektik also manufactures and supplies radiopharmaceutical products crucial for cancer diagnostics. In addition to these, it maintains a research laboratory dedicated to advancing diagnostic imaging systems and runs a service center for medical apparatus. The company further extends its services to include maintenance for medical equipment and the execution of essential acceptance and specialist tests.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
PLN394.00
+1.60 (+0.41%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
34.5K
Beta
0.03
Float Shares
3.96M
Free Float %
46.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.71% | +5.25% | +3.83% | +8.37% | +8.29% | +1.60% | +36.35% | +357.19% | +685.50% | +1,931.94% | +3,455.29% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
394.00
DCF (Unlevered)
2,448.87
+521.5%
DCF (Levered)
2,050.47
+420.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
80% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | -1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
8.51
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
★ Strong MOAT
-
Revenue growth Medical - Devices: +11.2%+9.2% Q1'26: +71.0% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+24.0% Q1'26: +1,956.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+12.8% Q1'26: -15.6% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+23.3% ★ Q1'26: +25.2% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+71.4% ★ Q1'26: +97.7% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-0.1% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.22× Q1'26: 0.24× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 4 Rev. Ana. 1 EPS Ana. |
Sep 2027 5 Rev. Ana. 1 EPS Ana. |
Sep 2028 4 Rev. Ana. 2 EPS Ana. |
Sep 2029 2 Rev. Ana. 1 EPS Ana. |
Sep 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
83.60M
est: 86.76M (-3.6%)
|
49.43M
est: 57.50M (-14.0%)
|
62.94M
est: 75.72M (-16.9%)
|
105.32M
est: 106.00M (-0.6%)
|
134.79M
est: 118.80M (+13.5%)
|
125.39M
est: 143.10M (-12.4%)
|
128.63M
est: 162.80M (-21.0%)
|
166.86M
est: 155.00M (+7.7%)
|
446.87M
est: 596.39M (-25.1%)
|
624.12M
est: 648.05M (-3.7%)
|
681.30M
est: 758.58M (-10.2%)
|
925.20M
884.75M – 950.07M
+22.0% YoY
|
890.77M
841.47M – 947.10M
-3.7% YoY
|
951.80M
942.10M – 961.50M
+6.9% YoY
|
1.04B
991.23M – 1.09B
+9.5% YoY
|
1.24B
1.18B – 1.30B
+19.2% YoY
|
| EBITDA |
3.66M
est: 16.32M (-77.6%)
|
4.35M
est: 10.82M (-59.8%)
|
7.92M
est: 14.24M (-44.4%)
|
11.43M
est: 19.94M (-42.7%)
|
17.71M
est: 22.35M (-20.7%)
|
18.08M
est: 26.92M (-32.8%)
|
17.90M
est: 30.62M (-41.6%)
|
26.48M
est: 29.16M (-9.2%)
|
82.36M
est: 112.18M (-26.6%)
|
121.88M
est: 121.90M (0.0%)
|
179.25M
est: 142.69M (+25.6%)
|
174.03M
166.42M – 178.71M
+22.0% YoY
|
167.55M
158.28M – 178.15M
-3.7% YoY
|
179.03M
177.21M – 180.86M
+6.9% YoY
|
196.11M
186.45M – 204.79M
+9.5% YoY
|
233.69M
222.18M – 244.03M
+19.2% YoY
|
| EBIT |
-639.1K
est: 12.62M (-105.1%)
|
2.26M
est: 8.36M (-72.9%)
|
5.37M
est: 11.01M (-51.2%)
|
8.44M
est: 15.42M (-45.2%)
|
12.48M
est: 17.28M (-27.8%)
|
12.00M
est: 20.81M (-42.3%)
|
10.71M
est: 23.68M (-54.8%)
|
13.75M
est: 22.54M (-39.0%)
|
67.58M
est: 86.74M (-22.1%)
|
105.35M
est: 94.26M (+11.8%)
|
158.53M
est: 110.33M (+43.7%)
|
134.57M
128.69M – 138.19M
+22.0% YoY
|
129.56M
122.39M – 137.75M
-3.7% YoY
|
138.44M
137.03M – 139.85M
+6.9% YoY
|
151.64M
144.17M – 158.35M
+9.5% YoY
|
180.70M
171.80M – 188.70M
+19.2% YoY
|
| Net Income |
-1.27M
est: 342.4K (-469.5%)
|
388.1K
est: 2.80M (-86.2%)
|
4.09M
est: 3.44M (+18.6%)
|
10.29M
est: 3.77M (+172.8%)
|
9.14M
est: 3.88M (+135.6%)
|
8.81M
est: 13.20M (-33.3%)
|
8.38M
|
10.30M
|
52.45M
est: 76.24M (-31.2%)
|
84.64M
est: 75.09M (+12.7%)
|
102.19M
est: 76.99M (+32.7%)
|
128.02M
120.22M – 135.83M
+66.3% YoY
|
136.23M
127.93M – 144.54M
+6.4% YoY
|
151.55M
145.00M – 158.11M
+11.2% YoY
|
147.09M
137.67M – 155.55M
-2.9% YoY
|
158.14M
148.01M – 167.23M
+7.5% YoY
|
| SGA |
10.76M
est: 9.37M (+14.8%)
|
11.04M
est: 6.21M (+77.8%)
|
10.96M
est: 8.18M (+34.1%)
|
17.93M
est: 11.45M (+56.7%)
|
16.69M
est: 12.83M (+30.1%)
|
14.14M
est: 15.45M (-8.5%)
|
14.41M
est: 17.58M (-18.0%)
|
28.27M
est: 16.74M (+68.9%)
|
46.57M
est: 64.39M (-27.7%)
|
43.05M
est: 69.97M (-38.5%)
|
58.07M
est: 81.91M (-29.1%)
|
99.90M
95.53M – 102.58M
+22.0% YoY
|
96.18M
90.86M – 102.26M
-3.7% YoY
|
102.77M
101.72M – 103.82M
+6.9% YoY
|
112.57M
107.03M – 117.55M
+9.5% YoY
|
134.15M
127.54M – 140.08M
+19.2% YoY
|
| EPS |
-0.15
est: 0.04 (-473.2%)
|
0.05
est: 0.33 (-84.8%)
|
0.48
est: 0.40 (+18.7%)
|
1.21
est: 0.44 (+173.2%)
|
1.07
est: 0.46 (+135.1%)
|
1.03
est: 1.55 (-33.5%)
|
0.98
|
1.26
|
6.15
est: 8.94 (-31.2%)
|
9.68
est: 8.84 (+9.5%)
|
11.98
est: 9.07 (+32.1%)
|
15.08
14.11 – 15.94
+66.3% YoY
|
16.04
15.02 – 16.97
+6.4% YoY
|
17.79
17.02 – 18.56
+10.9% YoY
|
17.27
16.16 – 18.26
-2.9% YoY
|
18.56
17.37 – 19.63
+7.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-06-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-06-10 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-06-09 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-06-08 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-06-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-06-03 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-06-02 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-06-01 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
77.31M
OE per share TTM
9.06
Owner's Yield
3.10%
Maintenance CapEx ratio
7.58%
Maint CapEx / Avg PPE
18.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 8 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Sophus Capital Emerging Market Small Cap ETF EMSC | 0.68% | 303.1K | 0.85% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.05% | 353.9K | 0.65% |
| 3 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.02% | 57.9K | 0.56% |
| 4 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.02% | 94.1K | 0.44% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.01% | 603.2K | 0.39% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.01% | 506.7K | 0.29% |
| 7 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 30.7K | 0.07% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 378.2K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
960.8K
Shares Outstanding
8.53M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cezary Dariusz Kozanecki | President of the Management Board & MD | — | male |
| Dariusz Marcin Korecki | Vice President of the Management Board | — | male |
| Jacek Krus | Deputy Administrative Director | — | male |
| Katarzyna Debowska | Chief Accountant | — | female |
| Piotr Kaszuba | Head of Technology Laboratory and Laboratory Technical Manager | — | male |
| Sawa Zuzanna Zarebinska | Secretary & Member of the Supervisory Board | — | female |
| Tomasz Wróbel | Member of the Management Board | — | male |
| Waldemar Wojciech Magnuszewski | Sales Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SNT.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
